Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT04981067
Active, not recruiting Not applicable

Dose-finding Study: Popliteal Sciatic Nerve Block in Patients Undergoing Diabetic Foot Surgery

NCT04981067 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Not applicable
Started
2021-08-24
Last updated
2026-04-30

Condition(s) studied

Diabetic FootDiabetic Neuropathies

Investigational drug(s) / intervention(s)

Maintain the concentration of ropivacaine as same as those used in the previous participantDecrease the ropivacaine concentration by 0.05% from the concentration used in the previous participantIncrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant

Maintain the concentration of ropivacaine as same as those used in the previous participant: Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment

Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant: Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment

Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant: Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.

Study summary

The purpose of this study was to determine the minimum effective dose of a local anesthetic for proper anesthesia for popliteal sciatic nerve block under ultrasound guidance in patients undergoing surgery for diabetic foot disease.

Eligibility

Sex
ALL
Min age
19 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients who can be operated under popliteal sciatic nerve block among patients undergoing surgery for diabetic foot disease Exclusion Criteria: 1. Infection of the popliteal region 2. Severe coagulation abnormality 3. Allergic reaction or hypersensitivity to local anesthetics 4. Neurological abnormalities other than diabetic neuropathy in the lower extremity of the operation site 5. When it is impossible to evaluate sensory blockage and motor blockage 6. When the patient refuses

Primary outcome measure(s)

  • Median effective anesthetic concentration 90 (MEAC 90) — within 30 minutes from the popliteal sciatic block
    Concentration of ropivacaine required for successful sciatic nerve block in 90% of all patients

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Hospital Seoul South Korea

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04981067 on ClinicalTrials.gov ↗ ← All trials in South Korea